
ShockWave Medical SWAV
Quarterly report 2024-Q1
added 05-06-2024
ShockWave Medical Book Value 2011-2026 | SWAV
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value ShockWave Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 669 M | 511 M | 242 M | 226 M | 193 M | 30.5 M | -83.3 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 669 M | -83.3 M | 255 M |
Quarterly Book Value ShockWave Medical
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 752 M | 601 M | 617 M | 571 M | 511 M | 356 M | 305 M | 268 M | 242 M | 220 M | 208 M | 204 M | 226 M | 226 M | 226 M | 226 M | 193 M | 193 M | 193 M | 193 M | 30.2 M | 30.2 M | 30.2 M | 30.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 752 M | 30.2 M | 277 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AxoGen
AXGN
|
129 M | $ 32.5 | -8.14 % | $ 1.44 B | ||
|
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
Aziyo Biologics
AZYO
|
-38.6 M | - | 1.37 % | $ 20.5 M | ||
|
Alphatec Holdings
ATEC
|
791 M | $ 13.77 | 4.86 % | $ 1.97 B | ||
|
Bio-Rad Laboratories
BIO
|
6.57 B | $ 269.87 | 0.53 % | $ 7.61 B | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
Apyx Medical Corporation
APYX
|
26.9 M | $ 3.53 | -1.12 % | $ 122 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
25.4 M | $ 14.58 | -1.22 % | $ 394 M | ||
|
Cognyte Software Ltd.
CGNT
|
217 M | $ 6.36 | 0.32 % | $ 457 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Bruker Corporation
BRKR
|
1.82 B | $ 39.87 | 0.77 % | $ 5.94 K | ||
|
BioSig Technologies
BSGM
|
-1.42 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 75.27 | 1.21 % | $ 111 B | ||
|
EDAP TMS S.A.
EDAP
|
40.9 M | $ 4.52 | - | $ 169 M | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
Electromed
ELMD
|
43.2 M | $ 23.17 | -5.16 % | $ 196 M | ||
|
CONMED Corporation
CNMD
|
1.03 B | $ 46.0 | 1.39 % | $ 1.43 B | ||
|
Second Sight Medical Products
EYES
|
17.6 M | - | -0.97 % | $ 54.4 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | ||
|
Delcath Systems
DCTH
|
68.7 M | $ 9.94 | 2.0 % | $ 283 M | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
InMode Ltd.
INMD
|
683 M | $ 14.0 | -1.41 % | $ 905 M | ||
|
Establishment Labs Holdings
ESTA
|
53.1 M | $ 78.78 | 5.1 % | $ 2.22 B | ||
|
IRadimed Corporation
IRMD
|
86.8 M | $ 99.04 | -2.22 % | $ 1.25 B | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
FONAR Corporation
FONR
|
146 M | $ 18.55 | -0.22 % | $ 122 M | ||
|
Globus Medical
GMED
|
4.57 B | $ 92.25 | -1.25 % | $ 12.5 B | ||
|
LivaNova PLC
LIVN
|
1.32 B | $ 69.26 | 1.32 % | $ 3.76 B | ||
|
Pulmonx Corporation
LUNG
|
85.8 M | $ 1.51 | 2.03 % | $ 59.1 M | ||
|
Helius Medical Technologies
HSDT
|
2.35 M | $ 1.88 | - | $ 1.14 M | ||
|
Medtronic PLC
MDT
|
48.3 B | $ 97.06 | -1.57 % | $ 125 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.55 B | $ 11.57 | -1.66 % | $ 891 M | ||
|
MiMedx Group
MDXG
|
193 M | $ 5.35 | 0.28 % | $ 786 M |